Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742387 | 0.92 | L3MBTL1 (0.39) | L3MBTL1MGLLTDP1MAPTLMNA | |
| SCHEMBL10132776 | 0.92 | L3MBTL1 (0.39) | L3MBTL1MGLLTDP1MAPTLMNA | |
| SCHEMBL6742804 | 0.91 | MGLL (0.42) | L3MBTL1MGLLTDP1GLACA12 | |
| SCHEMBL13265054 | 0.89 | MGLL (0.41) | L3MBTL1MGLLTDP1MAPTLMNA | |
| SCHEMBL6742430 | 0.89 | MGLL (0.41) | L3MBTL1MGLLTDP1MAPTLMNA | |
| SCHEMBL6742667 | 0.88 | MGLL (0.40) | L3MBTL1MGLLTDP1CA12CA1 | |
| SCHEMBL6742571 | 0.87 | CYP1A2 (0.41) | L3MBTL1MGLLTDP1MAPTLMNA | |
| SCHEMBL6792944 | 0.83 | MGLL (0.46) | L3MBTL1MGLLLMNACA12CA1 | |
| SCHEMBL6742394 | 0.83 | MGLL (0.46) | L3MBTL1MGLLLMNACA12CA1 | |
| SCHEMBL10132715 | 0.83 | MGLL (0.41) | L3MBTL1MGLLTDP1GLACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374788-A1 | INDANYL COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010074089-A1 | INDANYL COMPOUNDS | 第一三共株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | L3MBTL1 4719/4885MGLL 2051/4885TDP1 3917/4885 |
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | L3MBTL1 4401/4885MGLL 2501/4885TDP1 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.